Zollinger‑Ellison Gastroenteritis
Overview
Zollinger‑Ellison gastroenteritis (often simply called Zollinger‑Ellison syndrome, ZES) is a rare disorder in which one or more gastrin‑producing tumors (gastrinomas) arise in the pancreas or duodenum. The excess gastrin stimulates the stomach to secrete large amounts of acid, which then damages the lining of the stomach, duodenum, and even the jejunum, leading to a chronic inflammatory condition that can be described as “gastroenteritis.”
Key points:
- Who it affects: Adults 30‑60 years old, slightly more common in men.
- Prevalence: Approximately 1–3 cases per million population worldwide; about 10 % of patients with ZES develop hereditary forms (MEN‑1 syndrome).1
- Nature: A neuroendocrine tumor (NET) that is usually malignant (>60 % on diagnosis) and can metastasize to lymph nodes, liver, or bone.
Symptoms
The signs result from hyperacidic gastric secretions and the inflammatory response of the gastrointestinal (GI) tract.
- Severe, recurrent epigastric pain: Often described as burning or gnawing; may improve with antacids.
- Peptic ulcer disease (PUD): Multiple ulcers in unusual locations (duodenum beyond the first part, jejunum, colon).
- Diarrhea: 3–10 watery stools per day; can be fatty (steatorrhea) because acid inactivates pancreatic enzymes.
- Weight loss: Due to malabsorption, anorexia, and chronic pain.
- Nausea & vomiting: May contain bile if obstruction occurs.
- Gastro‑esophageal reflux disease (GERD) symptoms: Heartburn, sour taste.
- Gastrointestinal bleeding: Hematemesis or melena from ulcer erosion.
- Fatigue & anemia: Chronic blood loss leads to iron‑deficiency anemia.
- Abdominal distension & bloating: Result of slowed gastric emptying.
- Rare neurologic symptoms: In MEN‑1 patients, hyperparathyroidism or pituitary lesions may coexist.
Causes and Risk Factors
Primary cause
Zollinger‑Ellison syndrome is caused by gastrin‑secreting neuroendocrine tumors (gastrinomas). Approximately 25 % are sporadic, while 75 % are associated with hereditary syndromes.
Risk factors
- Multiple endocrine neoplasia type 1 (MEN‑1): Inherited mutation in the MEN1 gene; 10–20 % of ZES patients have MEN‑1.
- Family history of gastrinoma or MEN‑1.
- Chronic atrophic gastritis: May predispose to neuroendocrine cell hyperplasia (though not a direct cause).
- Age & gender: Peak incidence 30–60 years; slight male predominance (≈55 %).
- Smoking: Increases risk of neuroendocrine tumor development.
Diagnosis
Because symptoms overlap with common ulcer disease, a high index of suspicion is essential.
Laboratory tests
- Fasting serum gastrin level: >1000 pg/mL (normal < 100 pg/mL) strongly suggests ZES, especially after a secretin stimulation test.
- Secretin stimulation test: Paradoxical rise in gastrin after IV secretin is diagnostic; sensitivity ≈ 94 %.
- Chromogranin A (CgA): Elevated in 70–80 % of NETs, useful for monitoring.
- Acid output measurement (pH‑probe or gastric analysis): Baseline gastric pH < 2 indicates hyperacidity.
Imaging studies
- Endoscopic ultrasound (EUS): Detects small pancreatic or duodenal tumors (≤ 1 cm) with high resolution.
- Multiphasic contrast‑enhanced CT or MRI: Evaluates size, vascularity, and metastatic spread.
- Somatostatin receptor scintigraphy (SRS) / Ga‑68 DOTATATE PET‑CT: Gold standard for locating gastrinomas and assessing somatostatin‑receptor expression.
- Selective arterial calcium stimulation with hepatic venous sampling: Highly sensitive for occult gastrinomas when imaging is negative.
Pathology
If surgical resection is performed, histology confirms a well‑differentiated neuroendocrine tumor, graded by Ki‑67 index (G1–G3).
Treatment Options
Therapy targets two goals: suppress gastric acid to control symptoms, and remove or control the tumor.
Acid‑suppression therapy (first‑line)
- High‑dose proton pump inhibitors (PPIs): Omeprazole 60‑120 mg/day, Esomeprazole 40‑80 mg/day, or equivalent. PPIs normalize gastric pH in >90 % of patients.2
- Histamine‑2 receptor antagonists (H2RAs): Ranitidine or famotidine can be added for breakthrough symptoms, but PPIs are preferred.
- Long‑term PPI use requires monitoring for hypomagnesemia, B12 deficiency, and possible rebound hyperacidity.
Surgical management
- Curative resection: Enucleation or pancreaticoduodenectomy (Whipple) for localized gastrinomas.
- Liver metastases: Resection, radiofrequency ablation, or hepatic artery embolization.
- In MEN‑1 patients, surgery is more conservative because of multifocal disease; medical control is often first.
Medical therapies for tumor control
- Somatostatin analogues: Octreotide or lanreotide; inhibit gastrin release and may shrink tumors. Effective in ~30‑50 % of cases.
- Targeted therapy: Everolimus (mTOR inhibitor) and sunitinib (tyrosine‑kinase inhibitor) are approved for advanced pancreatic NETs.
- Chemotherapy: Streptozocin‑based regimens for high‑grade, rapidly progressive disease.
Other interventions
- Endoscopic ulcer therapy: Clip or cautery for actively bleeding ulcers.
- Pancreatic enzyme replacement: If malabsorption is severe, to improve nutrient absorption.
Living with Zollinger‑Ellison Gastroenteritis
Medication adherence
- Take PPIs exactly as prescribed; do not skip doses.
- Schedule regular labs (magnesium, calcium, vitamin B12) every 6–12 months.
Dietary adjustments
- Small, frequent meals: Reduces gastric acid spikes.
- Avoid trigger foods: Citrus, tomato‑based sauces, chocolate, caffeine, alcohol, and very spicy foods.
- Low‑fat diet: Fat slows gastric emptying and can exacerbate diarrhea.
- Hydration: Replace fluids lost through diarrhea; consider oral rehydration solutions.
Monitoring & follow‑up
- Clinic visits every 3–6 months initially, then annually if stable.
- Repeat imaging (CT/MRI or DOTATATE PET) every 12 months to detect recurrence.
- Track stool frequency, weight, and any new abdominal pain.
Psychosocial support
Living with a rare, chronic tumor can cause anxiety. Support groups (e.g., NET Patient Foundation) and counseling are beneficial.
Prevention
Because gastrinomas are largely sporadic or genetically predetermined, primary prevention is limited. However, risk can be reduced by:
- Genetic counseling: For families with MEN‑1 or known MEN1 mutations.
- Smoking cessation: Lowers neuroendocrine tumor risk.
- Regular medical review: In known MEN‑1 patients, annual gastrin testing can detect tumors early.
Complications
- Severe peptic ulcer disease: Perforation, hemorrhage, or obstruction.
- Gastrointestinal bleeding: May require endoscopic or surgical intervention.
- Malnutrition & electrolyte disturbances: Chronic diarrhea leads to potassium, magnesium, and bicarbonate loss.
- Metastatic disease: Liver, lymph nodes, bone metastases can cause pain, hepatic dysfunction, or spinal cord compression.
- Acid‑related esophagitis: Barrett’s esophagus, increasing esophageal cancer risk.
- Secondary infections: Long‑term PPI use can predispose to Clostridioides difficile colitis.
When to Seek Emergency Care
Call 911 or go to the nearest emergency department if you experience any of the following:
- Sudden, severe abdominal pain that does not improve with antacids.
- Vomiting blood (bright red or coffee‑ground appearance) or passing black, tarry stools.
- Rapid heart rate (>100 bpm), dizziness, or fainting – signs of significant blood loss.
- Persistent diarrhea (>8 watery stools in 24 hours) with signs of dehydration (dry mouth, reduced urine output, extreme thirst).
- High fever (>38.5 °C/101.3 °F) with abdominal pain – possible perforation or severe infection.
Sources:
- Mayo Clinic. Zollinger‑Ellison syndrome. Updated 2023. doi:10.1016/j.mayocp.2023.01.012
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Acid‑related disorders treatment guidelines, 2022.
- American Gastroenterological Association. Guidelines for the management of neuroendocrine tumors, 2021.
- World Health Organization. Classification of Neuroendocrine Tumors, 2020.
- Cleveland Clinic. MEN‑1 and Zollinger‑Ellison syndrome. Accessed 2024.